Enablex (Darifenacin) - Summary

ENABLEX SUMMARY

ENABLEX^® (darifenacin) is an extended-release tablet which contains 7.5 mg or 15 mg darifenacin as its hydrobromide salt. The active moiety, darifenacin, is a potent muscarinic receptor antagonist.

ENABLEX^®(darifenacin) extended-release tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.

ENABLEX NEWS HIGHLIGHTS

Published Studies Related to Enablex (Darifenacin)

Clinical relevance of health-related quality of life outcomes with darifenacin. [2008.07]

Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. [2007.10]

Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. [2006.11]

Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. [2006.05]

Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. [2006.01]

more>>

Clinical Trials Related to Enablex (Darifenacin)

Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects [Completed]

Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder [Completed]

Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder [Completed]

A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder [Completed]

Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over [Completed]

more>>